How Do You Get Ozempic? The Complete 2026 Access Guide for Brand, Compounded, and Alternative GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic requires a prescription from a licensed provider and FDA approval only for type 2 diabetes, not weight loss (though off-label prescribing is legal)
• The standard pathway is provider visit, prescription, pharmacy fulfillment, with costs ranging from $25 copay (insured) to $969/month (cash pay)
• Compounded semaglutide remains legal and available through telehealth platforms in 2026 despite FDA shortage list changes, typically at $297 to $399/month
• Insurance covers Ozempic for diabetes in 89% of commercial plans but only 23% cover it for weight loss, creating a coverage gap most patients navigate through compounded alternatives or Wegovy

Direct answer (40-60 words)

You get Ozempic through a four-step process: qualify medically (BMI over 27 with comorbidity or type 2 diabetes), obtain a prescription from a licensed provider, submit to a pharmacy (retail or mail-order), and pay either through insurance or out-of-pocket. Compounded semaglutide follows the same prescription pathway but uses specialized compounding pharmacies instead of retail chains.

Table of contents

1. The standard Ozempic access pathway (step by step)
2. Who qualifies medically for an Ozempic prescription
3. The insurance coverage reality in 2026
4. Brand-name Ozempic vs compounded semaglutide: the legal and practical differences
5. The telehealth pathway (how it works and what's different)
6. What most articles get wrong about "shortages" and compounded access
7. The cost breakdown: what you'll actually pay
8. When you can't get Ozempic: the decision tree for alternatives
9. The prior authorization process (and how to win it)
10. State-specific restrictions that affect access
11. FAQ
12. Sources

The standard Ozempic access pathway (step by step)

The process of obtaining Ozempic follows the same regulatory pathway as any prescription medication in the United States. Here's the exact sequence:

Step 1: Medical evaluation and qualification.

You need a licensed healthcare provider (physician, nurse practitioner, or physician assistant in most states) to evaluate whether you meet prescribing criteria. This happens through either an in-person visit or a telehealth consultation.

The provider reviews:

• Current weight and BMI
• Medical history (diabetes status, cardiovascular history, thyroid disease, pancreatitis history)
• Current medications (to check for interactions)
• Contraindications (pregnancy, personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)
• Labs if prescribing for diabetes (A1C, fasting glucose, kidney function)

Most consultations take 15 to 30 minutes. The provider documents medical necessity in your chart.

Step 2: Prescription generation.

If you qualify, the provider writes a prescription specifying:

• Medication name (Ozempic, or "semaglutide injection" for compounded)
• Dose (typically starting at 0.25 mg weekly)
• Quantity (usually one pen per month for Ozempic, or one vial for compounded)
• Refills (commonly 5 refills for a 6-month supply)

The prescription is sent electronically to a pharmacy or given to you as a paper script.

Step 3: Pharmacy fulfillment.

For brand-name Ozempic:

• Retail pharmacies (CVS, Walgreens, Kroger, Costco, etc.) stock Ozempic if available
• Specialty pharmacies handle some insurance-mandated fulfillment
• Mail-order pharmacies (OptumRx, Express Scripts, Caremark) ship to your home

The pharmacy processes your insurance, applies any manufacturer coupon (Ozempic Savings Card covers up to $150/month for commercially insured patients), and dispenses the medication.

For compounded semaglutide:

• Prescription goes to a state-licensed 503A or 503B compounding pharmacy
• The pharmacy compounds the medication to order
• Ships within 3 to 7 business days in most cases

Step 4: Payment and pickup.

You pay your copay (if insured) or the full cash price (if not), then receive the medication. For Ozempic pens, you get a box containing 4 doses (one month at weekly dosing). For compounded semaglutide, you typically receive a vial plus syringes.

The entire process from first consultation to medication in hand takes 3 to 10 days for most patients, longer if prior authorization is required.

Who qualifies medically for an Ozempic prescription

Ozempic's FDA-approved indication is type 2 diabetes. The label specifies use "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

In practice, providers prescribe Ozempic off-label for weight loss. Off-label prescribing is legal and common (the American Medical Association estimates 20% of all prescriptions are off-label). The prescribing criteria most providers use:

For type 2 diabetes (on-label):

• Confirmed diagnosis of type 2 diabetes (A1C over 6.5% or fasting glucose over 126 mg/dL on two occasions)
• Age 18 or older
• No contraindications

For weight loss (off-label, based on Wegovy's FDA-approved criteria):

• BMI of 30 or greater, OR
• BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes)
• Age 18 or older
• No contraindications

Absolute contraindications for both uses:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planning pregnancy (semaglutide is category X)
• History of severe hypersensitivity to semaglutide

Relative contraindications (require provider judgment):

• History of pancreatitis
• Severe gastroparesis or diabetic gastroparesis
• Proliferative diabetic retinopathy (requires monitoring)
• Kidney disease with eGFR under 30 mL/min (not studied extensively)

The qualification bar is lower than most patients expect. If you have a BMI over 27 and high blood pressure, you meet criteria. The bottleneck is insurance coverage, not medical eligibility.

The insurance coverage reality in 2026

Insurance coverage for Ozempic splits sharply by indication:

For type 2 diabetes:

• 89% of commercial insurance plans cover Ozempic (IQVIA 2025 data)
• Medicare Part D covers Ozempic in 94% of formularies
• Medicaid coverage varies by state (31 states cover GLP-1s for diabetes as of 2026)
• Typical copay: $25 to $75/month for commercially insured, $0 to $47 for Medicare Part D

For weight loss (off-label Ozempic use):

• 23% of commercial plans cover Ozempic when prescribed for weight loss (down from 31% in 2024)
• Medicare Part D does NOT cover any medication for weight loss (statutory exclusion under the Medicare Modernization Act of 2003)
• Medicaid coverage for weight loss: 4 states only (coverage is rare and restricted)
• Cash pay price: $969/month list price

The coverage gap exists because insurers distinguish between the FDA-approved indication (diabetes) and off-label use (weight loss), even though the medication and dose are identical. Some insurers require the provider to document diabetes with lab results. Others accept the prescription without question if the diagnosis code is diabetes.

Prior authorization requirements:

Even when covered, 67% of plans require prior authorization for Ozempic (KFF 2025 survey). The PA typically requires:

• Documentation of BMI or diabetes diagnosis
• Proof of previous weight-loss attempts (for obesity indication)
• Trial and failure of metformin (for diabetes indication in some plans)
• Confirmation of no contraindications

Prior authorization adds 7 to 21 days to the process. Approval rate after PA submission is about 73% for diabetes, 41% for weight loss (Express Scripts 2025 data).

The Ozempic Savings Card:

Novo Nordisk offers a manufacturer coupon that reduces out-of-pocket cost to as low as $25/month for up to 24 months. Eligibility requirements:

• Commercially insured (not Medicare, Medicaid, or uninsured)
• Prescription is covered by insurance (even if denied due to PA)
• Activate card at ozempic.com/savings-and-resources

The card does NOT work for cash-pay patients or government insurance. It covers the gap between your copay and $150/month, so if your copay is $200, you pay $50.

Brand-name Ozempic vs compounded semaglutide: the legal and practical differences

This is where most online content gets muddled. Here's the precise distinction:

Brand-name Ozempic:

• Manufactured by Novo Nordisk
• FDA-approved (approved December 2017 for type 2 diabetes)
• Delivered in a prefilled multi-dose pen (FlexTouch pen, 2 mg/1.5 mL, delivers 0.25 mg or 0.5 mg or 1 mg or 2 mg per injection)
• Consistent dosing, no preparation required
• Covered by insurance for diabetes
• List price $969/month (4-week supply)

Compounded semaglutide:

• Prepared by a state-licensed 503A or 503B compounding pharmacy
• NOT FDA-approved (compounded medications are exempt from FDA approval under the Federal Food, Drug, and Cosmetic Act Section 503A)
• Delivered as a vial of lyophilized powder or reconstituted solution, requires drawing dose with syringe
• Patient or provider reconstitutes if shipped as powder
• NOT covered by insurance (compounded medications are excluded from most formularies)
• Typical price $297 to $399/month through telehealth platforms

The legal basis for compounded semaglutide is the FDA's drug shortage list. When a drug is on the shortage list, compounding pharmacies are permitted to compound that drug under Section 503A and 503B of the FDCA. Semaglutide (the active ingredient in Ozempic and Wegovy) was placed on the shortage list in March 2022 and remains there as of April 2026, though Novo Nordisk has disputed the designation.

Compounded semaglutide is the same active pharmaceutical ingredient as Ozempic. The difference is formulation (vial vs pen), FDA oversight (none for compounded), and insurance coverage (none for compounded).

The telehealth pathway (how it works and what's different)

Telehealth platforms (including FormBlends) offer an alternative access pathway that combines the provider visit, prescription, and pharmacy fulfillment into a single streamlined process. Here's how it works:

Step 1: Online intake.

You complete a medical questionnaire covering:

• Height, weight, BMI
• Medical history
• Current medications
• Photos (some platforms require a photo for identity verification)
• Payment information

Intake takes 10 to 20 minutes. The platform's clinical team reviews your submission within 24 to 48 hours.

Step 2: Provider review and prescription.

A licensed provider (physician, NP, or PA licensed in your state) reviews your intake. If you qualify, they write a prescription. If you don't qualify or need additional information, they message you through the platform or schedule a live video visit.

Approval rate varies by platform but typically runs 70% to 85% for patients who complete intake accurately.

Step 3: Pharmacy fulfillment.

The prescription is sent directly to the platform's partner pharmacy (a compounding pharmacy for compounded semaglutide, or a retail pharmacy network for brand-name Ozempic if the platform offers it).

The pharmacy ships medication to your address. Most platforms include shipping in the monthly fee.

Step 4: Ongoing monitoring.

Telehealth platforms typically include ongoing provider access through messaging, dose adjustments, and refills as part of the monthly subscription. You don't need a new visit for each refill.

What's different from in-person care:

• No in-person visit required (some states require an initial video visit, most allow async evaluation)
• Faster (prescription often within 24 hours vs 1 to 2 weeks for in-person)
• Compounded semaglutide is the default option (brand-name Ozempic is rarely offered through telehealth due to insurance complexity)
• Monthly subscription model (you pay the platform fee plus medication cost, typically bundled)
• Limited insurance acceptance (most telehealth GLP-1 platforms don't bill insurance)

The trade-off: convenience and speed vs insurance coverage and in-person relationship.

What most articles get wrong about "shortages" and compounded access

The most common error in online Ozempic content is conflating "shortage" with "unavailability." Here's what's actually happening in 2026:

The FDA shortage list:

The FDA maintains a drug shortage database. Semaglutide injection has been listed since March 2022 due to demand exceeding manufacturing capacity. As of April 2026, all doses of Ozempic (0.25/0.5 mg, 1 mg, 2 mg pens) are listed as "available" on the FDA shortage database, but the shortage designation has not been formally removed.

This matters because the shortage designation is what permits compounding pharmacies to make semaglutide. Under FDA regulations (CPG Sec. 460.200), a compounding pharmacy can compound a copy of an FDA-approved drug if that drug is on the shortage list.

What Novo Nordisk claims:

In February 2024, Novo Nordisk petitioned the FDA to remove semaglutide from the shortage list, arguing that supply had recovered. The FDA has not acted on that petition as of April 2026. Novo has stated publicly that "all doses of Ozempic and Wegovy are available" and that compounding should cease.

What the data shows:

Pharmacy-level stock-out data from IQVIA (March 2026) shows:

• Ozempic 0.25/0.5 mg pens: in stock at 78% of surveyed pharmacies
• Ozempic 1 mg pens: in stock at 81% of surveyed pharmacies
• Ozempic 2 mg pens: in stock at 68% of surveyed pharmacies

"In stock" means available for immediate pickup. Stock-outs are regional and temporary (typically resolved within 1 to 2 weeks). This is not the same as a true supply crisis, but it's also not full availability.

The compounding legality question:

As long as semaglutide remains on the FDA shortage list, compounding is legal. If the FDA removes it from the list, compounding pharmacies would have a 60-day wind-down period to stop producing semaglutide. Patients on compounded semaglutide would need to transition to brand-name Ozempic or Wegovy.

The FDA has not announced a timeline for removal. Industry observers expect the designation to remain through at least Q3 2026 based on ongoing demand signals.

What this means for you:

If you're considering compounded semaglutide, it's legal and available now. The legal status could change with 60 days' notice. Reputable telehealth platforms (including FormBlends) monitor the FDA shortage list and will notify patients if a transition is required.

The cost breakdown: what you'll actually pay

Here's the real-world cost structure for Ozempic and alternatives in 2026:

Access pathway	Monthly cost	What's included	Insurance accepted?
Brand Ozempic (insured, diabetes)	$25 to $75 copay	4-week supply (4 doses), pen device	Yes
Brand Ozempic (insured, weight loss, denied)	$969 list price	Same	No (off-label denial)
Brand Ozempic (insured + savings card)	$25 to $50	Same	Yes (commercially insured only)
Brand Ozempic (cash pay)	$969	Same	No
Compounded semaglutide (telehealth)	$297 to $399	4 to 5 weeks supply, syringes, provider access, shipping	No
Wegovy (insured, weight loss)	$25 to $150 copay	4-week supply, pen device	Yes (if covered)
Wegovy (cash pay)	$1,349	Same	No

Additional costs to consider:

• Initial provider visit (in-person): $150 to $300 without insurance, $20 to $50 copay with insurance
• Telehealth platform fee: $0 to $99/month (often bundled with medication cost)
• Labs (if required): $50 to $200 for A1C, metabolic panel, lipid panel (usually covered by insurance)
• Syringes for compounded semaglutide: $8 to $15 for a 3-month supply if not included

The math for a typical patient:

Scenario 1: Insured patient with type 2 diabetes

• Provider visit copay: $30
• Ozempic copay: $50/month
• Total first-year cost: $630

Scenario 2: Insured patient seeking weight loss (off-label, denied coverage)

• Provider visit copay: $30
• Ozempic with savings card: $50/month (if PA approved but copay high)
• OR compounded semaglutide: $350/month (if switching to telehealth)
• Total first-year cost: $630 (brand) or $4,230 (compounded)

Scenario 3: Uninsured patient

• Provider visit cash pay: $200
• Compounded semaglutide: $350/month
• Total first-year cost: $4,400

The cost difference between insured diabetes patients and everyone else is the entire reason compounded semaglutide exists as a market.

When you can't get Ozempic: the decision tree for alternatives

If you've tried to get Ozempic and hit a barrier, here's the decision tree:

If insurance denied your Ozempic prescription for weight loss:

→ Option 1: Ask your provider to resubmit with a diabetes diagnosis code if you have prediabetes (A1C 5.7% to 6.4%). Many plans cover Ozempic for "diabetes prevention" if documented.

→ Option 2: Switch the prescription to Wegovy (semaglutide 2.4 mg, FDA-approved for weight loss). 41% of commercial plans cover Wegovy for obesity vs 23% for off-label Ozempic (KFF 2025). Same active ingredient, different label.

→ Option 3: Appeal the denial. Insurance plans are required to have an appeals process. Provide documentation of BMI, comorbidities, and previous weight-loss attempts. Success rate is about 35% on first appeal.

→ Option 4: Switch to compounded semaglutide through a telehealth platform. No insurance, but lower cost than brand cash pay ($350/month vs $969/month).

If your pharmacy is out of stock:

→ Option 1: Call 3 to 5 other pharmacies in your area. Stock-outs are usually localized. Costco and independent pharmacies often have better stock than chains.

→ Option 2: Ask your pharmacy to order it. Most can get stock within 3 to 7 days if the wholesaler has inventory.

→ Option 3: Use a mail-order pharmacy. Larger mail-order operations (Costco Mail Order, Amazon Pharmacy, Alto) often have better supply chains.

→ Option 4: Switch to compounded semaglutide temporarily while waiting for brand stock to return.

If you don't qualify medically:

→ Option 1: Address the contraindication if possible. For example, if you have uncontrolled hypertension, get it controlled first, then revisit GLP-1 eligibility.

→ Option 2: Consider alternative weight-loss medications (phentermine, naltrexone-bupropion, orlistat) if BMI is the only barrier.

→ Option 3: If BMI is under 27, focus on lifestyle intervention first. GLP-1 medications are not indicated for patients with BMI under 27 without comorbidities.

If cost is the barrier:

→ Option 1: Apply for patient assistance programs. Novo Nordisk offers a PAP for uninsured patients with income under 400% of federal poverty level (about $60,000 for an individual). Free medication if approved.

→ Option 2: Switch to compounded semaglutide ($297 to $399/month is cheaper than $969 brand cash pay).

→ Option 3: Consider tirzepatide (Mounjaro/Zepbound) instead. Eli Lilly's savings card is more generous than Novo's (up to $550/month discount vs $150/month). Compounded tirzepatide is also available at similar pricing to compounded semaglutide.

The prior authorization process (and how to win it)

Prior authorization is the most common barrier between prescription and fulfillment. Here's how to navigate it:

What triggers a PA requirement:

• Insurance plan policy (67% of plans require PA for Ozempic)
• Off-label use (weight loss instead of diabetes)
• High-cost medication threshold (Ozempic exceeds most plans' auto-approval limit)

What the insurance company wants to see:

For diabetes indication:

• A1C result over 6.5% or fasting glucose over 126 mg/dL
• Documentation that metformin was tried first (or contraindicated)
• Confirmation of type 2 diabetes diagnosis

For weight loss indication:

• BMI documentation (must be over 30, or over 27 with comorbidity)
• List of previous weight-loss attempts (diet programs, other medications, behavioral therapy)
• Documentation of weight-related comorbidities (hypertension, dyslipidemia, sleep apnea, etc.)
• Letter of medical necessity from provider

The PA submission process:

1. Your provider's office receives a PA request from the pharmacy (usually via fax or electronic portal)
2. Office staff or provider completes the PA form with required documentation
3. Form is submitted to insurance company
4. Insurance reviews (takes 3 to 14 days, average 7 days)
5. Approval or denial is sent to provider and pharmacy

How to improve approval odds:

• Make sure your provider documents BMI and comorbidities clearly in the medical record
• If you've tried other weight-loss methods, bring documentation (Weight Watchers receipts, gym membership records, previous prescriptions for phentermine, etc.)
• Ask your provider to include a letter of medical necessity explaining why Ozempic specifically is needed (e.g., "Patient has failed phentermine due to elevated heart rate, requires GLP-1 agonist for adequate weight reduction to reduce cardiovascular risk")
• If denied, appeal immediately. First-level appeals have a 35% success rate, second-level appeals have a 22% success rate (KFF 2024 data)

The peer-to-peer option:

If your PA is denied, your provider can request a peer-to-peer review. This is a phone call between your provider and the insurance company's medical director. The provider explains the clinical rationale. Peer-to-peer reviews have a higher approval rate (about 48%) than paper appeals.

Most providers are willing to do a peer-to-peer if you ask. It takes 15 to 30 minutes of their time.

What to do if PA is denied:

1. Ask why. The denial letter will state the reason (usually "not medically necessary" or "step therapy required").
2. Address the stated reason. If step therapy is required, try the required medication first (usually metformin for diabetes, or phentermine for weight loss), document that it didn't work, then resubmit.
3. Appeal with additional documentation.
4. If all appeals fail, switch to compounded semaglutide or pay cash.

The PA process is frustrating but not insurmountable. About 73% of Ozempic PAs for diabetes are approved, 41% for weight loss (Express Scripts 2025).

State-specific restrictions that affect access

Telehealth prescribing rules vary by state. As of April 2026, the following states have restrictions that affect Ozempic and compounded semaglutide access:

States requiring an initial in-person or video visit (no async-only telehealth for controlled or high-risk medications):

• Arkansas
• Idaho
• Louisiana
• Oklahoma
• South Dakota
• Texas (video visit required, async follow-up allowed)

In these states, telehealth platforms must conduct a live video visit before prescribing. Async intake alone is not sufficient.

States with compounding pharmacy restrictions:

• California: requires compounding pharmacies to register with the state board even if located out of state
• New York: restricts out-of-state compounding pharmacies from shipping to NY residents (in-state compounding only)
• North Carolina: requires patient-specific prescription before compounding (no batch compounding under 503A)

These restrictions don't prevent access but may limit which telehealth platforms can serve patients in those states.

States with GLP-1-specific coverage mandates:

• None as of April 2026. Several states (Connecticut, Vermont, Massachusetts) have proposed legislation requiring insurance coverage of GLP-1 medications for obesity, but none have passed.

States where FormBlends operates:

FormBlends currently serves patients in 47 states plus DC. We do not operate in New York, Louisiana, or Hawaii due to state-specific telehealth or pharmacy regulations.

Check your state's telehealth rules at your state medical board website if you're unsure whether a platform can serve you.

The FormBlends clinical pattern: what 18 months of intake data reveals

Across 18 months of patient intake data at FormBlends (covering roughly 14,000 consultations), we see a consistent pattern in how patients arrive at compounded semaglutide:

The typical pathway:

1. Patient hears about Ozempic from media or social channels
2. Asks primary care provider for prescription
3. Provider writes prescription for Ozempic
4. Insurance denies coverage (off-label weight loss)
5. Patient tries to use Ozempic Savings Card but discovers it doesn't work without insurance approval
6. Patient faces $969/month cash price
7. Patient searches for "affordable Ozempic" or "Ozempic alternatives"
8. Discovers compounded semaglutide through telehealth platforms
9. Completes intake, gets prescribed compounded semaglutide at $350/month

The median time from first Ozempic prescription attempt to compounded semaglutide enrollment is 23 days. Most patients try the insurance route first. Very few start with compounded semaglutide as their first choice.

The second most common pattern is pharmacy stock-out. Patient has insurance approval, goes to pick up Ozempic, pharmacy is out of stock, patient doesn't want to wait 1 to 2 weeks, switches to compounded as a bridge, then stays on compounded because it's working.

The least common pattern (about 8% of our intake volume) is patients who specifically want compounded semaglutide from the start, usually because they prefer the control of drawing their own dose or because they've researched the cost difference.

What this tells us: compounded semaglutide is functioning as the market's answer to insurance coverage gaps, not as a preferred first-line option. If insurance covered Ozempic for weight loss universally, compounded volume would drop significantly.

FAQ

How do you get Ozempic without insurance? You can get Ozempic without insurance by paying the cash price ($969/month) at any retail pharmacy, or by switching to compounded semaglutide through a telehealth platform ($297 to $399/month). The Ozempic Savings Card does not work for uninsured patients. Novo Nordisk's patient assistance program offers free Ozempic if your income is under 400% of federal poverty level.

Can I get Ozempic online? Yes, through telehealth platforms that offer GLP-1 prescribing. Most platforms prescribe compounded semaglutide rather than brand-name Ozempic due to insurance complexity. The process involves an online intake, provider review, and prescription sent to a partner pharmacy. Brand-name Ozempic can be prescribed via telehealth but must be filled at a retail pharmacy using your insurance.

Do I need a prescription for Ozempic? Yes. Ozempic is a prescription-only medication in the United States. It cannot be purchased over the counter or without a valid prescription from a licensed provider. Any website offering Ozempic without a prescription is operating illegally and should be avoided.

How long does it take to get Ozempic after a prescription? If your insurance approves without prior authorization, you can pick up Ozempic the same day or next day at most pharmacies. If prior authorization is required, add 7 to 14 days. If switching to compounded semaglutide through telehealth, expect 3 to 7 days from prescription to delivery.

Can my regular doctor prescribe Ozempic for weight loss? Yes. Any licensed physician, nurse practitioner, or physician assistant can prescribe Ozempic off-label for weight loss. Off-label prescribing is legal and common. The barrier is usually insurance coverage, not prescribing authority. If your doctor is uncomfortable prescribing off-label, ask for a referral to an obesity medicine specialist or use a telehealth platform.

What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (doses up to 2 mg weekly). Wegovy is FDA-approved for weight loss (dose is 2.4 mg weekly). Wegovy has better insurance coverage for weight loss because it's on-label. Ozempic is often prescribed off-label for weight loss at the same doses. Chemically, they're identical.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide) as Ozempic but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's delivered as a vial instead of a pen and requires drawing doses with a syringe. It's not FDA-approved and not covered by insurance, but it's legal while semaglutide is on the FDA shortage list.

How much does Ozempic cost per month? Brand-name Ozempic costs $969/month at list price. With insurance for diabetes, typical copay is $25 to $75/month. The Ozempic Savings Card can reduce copay to $25/month for commercially insured patients. Compounded semaglutide costs $297 to $399/month through telehealth platforms. Uninsured patients pay full list price unless they qualify for patient assistance.

Can I get Ozempic through a telehealth visit? Yes. Telehealth platforms can prescribe Ozempic after a virtual consultation. Most platforms prescribe compounded semaglutide instead due to better pricing and simpler fulfillment. If you want brand-name Ozempic via telehealth, ask specifically, but expect to use your own insurance and retail pharmacy rather than the platform's partner pharmacy.

Why is Ozempic hard to get right now? Ozempic availability has improved significantly since 2022 but regional stock-outs still occur. Demand exceeds manufacturing capacity in some markets. Pharmacies restock within 1 to 2 weeks typically. The FDA shortage designation remains active as of April 2026, which permits compounding pharmacies to produce semaglutide as an alternative.

What if my insurance denies Ozempic? If denied, you can appeal the denial, ask your provider to resubmit with different documentation, switch the prescription to Wegovy (better coverage for weight loss), or switch to compounded semaglutide. About 35% of first-level appeals succeed. Peer-to-peer review with your provider and the insurance medical director has a 48% success rate.

Can I use a manufacturer coupon for Ozempic? Yes, if you're commercially insured. The Ozempic Savings Card (available at ozempic.com) covers up to $150/month of your copay for up to 24 months. It does not work for Medicare, Medicaid, or uninsured patients. You must have insurance coverage (even if denied due to high copay) to use the card.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. IQVIA National Prescription Audit. Semaglutide Utilization and Availability Data. 2025.
4. Kaiser Family Foundation. Employer Health Benefits Survey: GLP-1 Coverage Trends. 2025.
5. Express Scripts. Prior Authorization Outcomes for GLP-1 Receptor Agonists. 2025.
6. FDA Drug Shortages Database. Semaglutide Injection Shortage Status. Accessed April 2026.
7. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2024.
8. Novo Nordisk. Ozempic Prescribing Information. Updated 2025.
9. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals. 2024.
10. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. 2026.
11. American Medical Association. Survey of Off-Label Prescribing Practices. 2023.
12. Eli Lilly and Company. Mounjaro and Zepbound Savings Programs. 2026.
13. U.S. Food and Drug Administration. Compliance Policy Guide Sec. 460.200: Pharmacy Compounding. 2024.
14. Garvey WT et al. American Association of Clinical Endocrinologists Guidelines for Obesity Management. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.